Fig. 6.

IL-2 contributes to the anti-myeloma activity of elotuzumab (Elo) in combination with lenalidomide (Len). a Neutralization of IL-2 with an anti-IL-2 mAb decreases myeloma cell killing in Elo (P < 0.05 vs. Elo + cIgG1)- or Elo + Len (P < 0.01 vs. Elo + Len + cIgG1)-treated PBL/myeloma cell co-cultures on day 3 (n = 7). Enhancement of myeloma cell killing by graded doses of IL-2 (units/mL) in myeloma cell co-cultures with b PBL or c purified NK cells at 24 h. Representative data from one of the three donors is shown b, c